Selective inhibitors of mTORC1 activate 4EBP1 and suppress tumor growth

The nf-core framework for community-curated bioinformatics pipelines

(2020) Philip A. Ewels et al.   NATURE BIOTECHNOLOGY

Generally applicable transcriptome-wide analysis of translation using anota2seq

(2019) Christian Oertlin et al.   NUCLEIC ACIDS RESEARCH

Translational offsetting as a mode of estrogen receptor α‐dependent regulation of gene expression

(2019) Julie Lorent et al.   EMBO JOURNAL

Cryo-EM structure of human mTOR complex 2

(2018) Xizi Chen et al.   CELL RESEARCH

A phase II study of the dual mTOR inhibitor MLN0128 in patients with metastatic castration resistant prostate cancer

(2018) Laura Graham et al.   INVESTIGATIONAL NEW DRUGS

Signaling Pathways Involved in the Regulation of mRNA Translation

(2018) Philippe P. Roux et al.   MOLECULAR AND CELLULAR BIOLOGY

mTOR-sensitive translation: Cleared fog reveals more trees

(2017) Laia Masvidal et al.   RNA Biology

A Randomised Phase 2 Study of AZD2014 Versus Everolimus in Patients with VEGF-Refractory Metastatic Clear Cell Renal Cancer

(2016) Thomas Powles et al.   EUROPEAN UROLOGY

nanoCAGE reveals 5′ UTR features that define specific modes of translation of functionally related MTOR-sensitive mRNAs

(2016) Valentina Gandin et al.   GENOME RESEARCH

Overcoming mTOR resistance mutations with a new-generation mTOR inhibitor

(2016) Vanessa S. Rodrik-Outmezguine et al.   NATURE

First-in-Human Pharmacokinetic and Pharmacodynamic Study of the Dual m-TORC 1/2 Inhibitor AZD2014

(2015) B. Basu et al.   CLINICAL CANCER RESEARCH

Integrative analysis of RNA, translation, and protein levels reveals distinct regulatory variation across humans

(2015) Can Cenik et al.   GENOME RESEARCH

Targeting the translation machinery in cancer

(2015) Mamatha Bhat et al.   NATURE REVIEWS DRUG DISCOVERY

limma powers differential expression analyses for RNA-sequencing and microarray studies

(2015) Matthew E. Ritchie et al.   NUCLEIC ACIDS RESEARCH

Full-length RNA-seq from single cells using Smart-seq2

(2014) Simone Picelli et al.   Nature Protocols

Inhibition of PI3K/mTOR Leads to Adaptive Resistance in Matrix-Attached Cancer Cells

(2012) Taru Muranen et al.   CANCER CELL

Hepatic mTORC2 Activates Glycolysis and Lipogenesis through Akt, Glucokinase, and SREBP1c

(2012) Asami Hagiwara et al.   Cell Metabolism

A unifying model for mTORC1-mediated regulation of mRNA translation

(2012) Carson C. Thoreen et al.   NATURE

Distinct perturbation of the translatome by the antidiabetic drug metformin

(2012) O. Larsson et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

The Best of Both Worlds? Bitopic Orthosteric/Allosteric Ligands of G Protein–Coupled Receptors

(2011) Celine Valant et al.   Annual Review of Pharmacology and Toxicology

AKT Inhibition Relieves Feedback Suppression of Receptor Tyrosine Kinase Expression and Activity

(2011) Sarat Chandarlapaty et al.   CANCER CELL

PI3K inhibition results in enhanced HER signaling and acquired ERK dependency in HER2-overexpressing breast cancer

(2011) V Serra et al.   ONCOGENE

mTOR Kinase Inhibition Causes Feedback-Dependent Biphasic Regulation of AKT Signaling

(2011) V. S. Rodrik-Outmezguine et al.   Cancer Discovery

Rational design of dualsteric GPCR ligands: quests and promise

(2010) Klaus Mohr et al.   BRITISH JOURNAL OF PHARMACOLOGY

Genetic Dissection of the Oncogenic mTOR Pathway Reveals Druggable Addiction to Translational Control via 4EBP-eIF4E

(2010) Andrew C. Hsieh et al.   CANCER CELL

4E-BP1 Is a Key Effector of the Oncogenic Activation of the AKT and ERK Signaling Pathways that Integrates Their Function in Tumors

(2010) Qing-Bai She et al.   CANCER CELL

Regulation of the mTOR Complex 1 Pathway by Nutrients, Growth Factors, and Stress

(2010) Shomit Sengupta et al.   MOLECULAR CELL

mTORC1-Mediated Cell Proliferation, But Not Cell Growth, Controlled by the 4E-BPs

(2010) R. J. O. Dowling et al.   SCIENCE

A scaling normalization method for differential expression analysis of RNA-seq data

(2010) Mark D Robinson et al.   GENOME BIOLOGY

p53-Dependent Translational Control of Senescence and Transformation via 4E-BPs

(2009) Emmanuel Petroulakis et al.   CANCER CELL

Biochemical, Cellular, and In vivo Activity of Novel ATP-Competitive and Selective Inhibitors of the Mammalian Target of Rapamycin

(2009) K. Yu et al.   CANCER RESEARCH

An ATP-competitive Mammalian Target of Rapamycin Inhibitor Reveals Rapamycin-resistant Functions of mTORC1

(2009) Carson C. Thoreen et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Active-Site Inhibitors of mTOR Target Rapamycin-Resistant Outputs of mTORC1 and mTORC2

(2009) Morris E Feldman et al.   PLOS BIOLOGY

PTEN and the PI3-Kinase Pathway in Cancer

(2008) Nader Chalhoub et al.   Annual Review of Pathology-Mechanisms of Disease

Sirolimus for Angiomyolipoma in Tuberous Sclerosis Complex or Lymphangioleiomyomatosis

(2008) John J. Bissler et al.   NEW ENGLAND JOURNAL OF MEDICINE

Rapamycin differentially inhibits S6Ks and 4E-BP1 to mediate cell-type-specific repression of mRNA translation

(2008) A. Y. Choo et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Control of eIF4E cellular localization by eIF4E-binding proteins, 4E-BPs

(2008) L. Rong et al.   RNA